Anvifen, capsules 250 mg 20 pcs

Pharmacological action – anti-aggregant, tranquilizing, nootropic, anticonvulsant, antioxidant.

Pharmacodynamics

Notropic, facilitates GABA-mediated transmission of nerve impulses in the CNS (direct effect on GABAergic receptors). The tranquilizing effect is combined with an activating effect. It also has antiaggregant, antioxidant and some anticonvulsant effects.

It improves the functional state of the brain by normalizing its metabolism and influence on the cerebral blood flow (increases the volumetric and linear velocity, reduces the vascular resistance, improves microcirculation, has an anti-aggregant effect). It lengthens the latent period and shortens the duration and severity of nystagmus.

It does not affect the choline and adrenoreceptors. It reduces vaso-vegetative symptoms (including headache, feeling of heaviness in the head, sleep disorders, irritability, emotional lability). With a course of treatment improves physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).

Limits manifestations of asthenia (improves well-being, increases interest and initiative – motivation of activity) without sedation or agitation.

Contributes to reducing feelings of anxiety, tension and restlessness, normalizes sleep.

In the elderly it does not cause CNS depression, muscular relaxant aftereffects are most often absent.

Pharmacokinetics

Absorption and distribution

. Absorption is high, penetrates well into all body tissues and through the BBB (about 0.1% of the administered dose penetrates into brain tissue, and to a greater extent in young and elderly persons). It is evenly distributed in the liver and kidneys.

Metabolism and excretion

Metabolized in the liver – 80-95%, metabolites are pharmacologically inactive. It does not cumulate. After 3 hours it is eliminated by the kidneys, while the concentration in the brain tissue is not decreased and is detectable for another 6 hours. About 5% is excreted unchanged by kidneys, partially in bile.

Indications

Asthenic and anxiety-neurotic conditions. Stuttering, tics and bedwetting in children.

Insomnia and nocturnal anxiety in the elderly.

Meniere’s disease, dizziness associated with dysfunctions of the vestibular analyzer of various genesis; prevention of motion sickness in kinetosis.

In complex therapy of alcohol withdrawal syndrome for relieving psychopathological and somatovegetative disorders.

Active ingredient

Composition

Active ingredient:

aminophenyl butyric acid hydrochloride – 250 mg

Auxiliary substances:

iprolose – 2 mg;

colloidal silicon dioxide – 8 mg;

p> lactose – 86.5 mg;

magnesium stearate – 3.5 mg

Hard gelatin capsule:

for 250 mg dosage – water, gelatin, azorubin dye (E122), brilliant blue dye (E133), titanium dioxide (E171)

How to take, the dosage

Overly, after meals, in 2-3-week courses.

Adults and children from 14 years of age – 250-500 mg 3 times a day (maximum daily dose – 2500 mg). Children 3-8 years – 50-100 mg 3 times a day; 8 – 14 years – 250 mg 3 times a day.

The single maximum dose in adults and children from 14 years of age is 750 mg, in persons over 60 years – 500 mg, for children under 8 years – 150 mg, from 8 to 14 years – 250 mg.

Alcohol withdrawal syndrome: 250-500 mg 3 times a day and at night 750 mg, with gradual reduction of the daily dose to the usual adult dose.

The treatment of vertigo in vestibular dysfunction and Meniere’s disease: 250 mg 3 times a day for 14 days.

Prevention of motion sickness: 250-500 mg once, 1 hour before the expected onset of motion sickness or when the first symptoms of seasickness appear.

The anti-sickness effect of Anvifen increases with increasing the dose of the drug. In the onset of marked manifestations of seasickness (vomiting, etc.) the prescription of Anvifen is ineffective even in doses of 750-1000 mg.

Interaction

Longens and enhances the effects of sleeping pills, narcotic analgesics, neuroleptics, anti-Parkinsonian and antiepileptic drugs.

Special Instructions

In long-term use, liver and peripheral blood function parameters should be periodically monitored.

Impact on the ability to drive vehicles and operate machinery.

Potentially hazardous activities requiring increased concentration should be avoided.

Contraindications

Hypersensitivity, pregnancy, breast-feeding, children under 3 years of age.

With caution: with erosive ulcerative lesions of the gastrointestinal tract, liver failure.

Side effects

Sleepiness, nausea. Increased irritability, agitation, anxiety, dizziness, headache (at first administration), allergic reactions.

Overdose

Symptoms: pronounced somnolence, nausea, vomiting, fatty liver dystrophy (intake more than 7 g), eosinophilia, decreased BP, impaired renal function.

Treatment: gastric lavage, administration of activated charcoal and symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy and during lactation (breastfeeding).

Similarities